Prescriber Insight Survey
*
1.
First Name
(Required.)
*
2.
Last Name
(Required.)
*
3.
Email Address
(Required.)
*
4.
Specialty
(Required.)
Primary Care
Oncologist
Endocrinologist
Rheumatologist
Other
*
5.
On a scale from 1 to 5, where 1 means "Not Important" and 5 means "Extremely important", how important is the financial reimbursement when treating your patients with denosumab (Prolia or XGEVA)? Please explain your reasoning.
(Required.)
1: Not Important
2: Slightly Important
3: Moderately Important
4: Very Important
5: Extremely Important
*
6.
Please explain your reasoning to question 5.
(Required.)
*
7.
On a scale from 1 to 5, where 1 means "Not Comfortable at All" and 5 means "Extremely Comfortable", how comfortable are you switching a stable Prolia/Xgeva patient to a biosimilar?
(Required.)
1: Not Comfortable at All
2: Slightly Comfortable
3: Moderately Comfortable
4: Very Comfortable
5: Extremely Comfortable
*
8.
Please explain your reasoning to question 7.
(Required.)
*
9.
Assume you are in a situation where you have 5 denosumab options (the originator brand and 4 new biosimilars). Also assume that the clinical profile, commercial payer coverage and financials are all highly similar for all options. Also assume that 4 of the denosumabs have a permanent reimbursement code and 1 option, Product X, does not, and requires a Miscellaneous code for reimbursement. On a scale from 1 to 5, where 1 means "No Negative Impact" and 5 means "Extremely Negative Impact," to what extent would the use of a miscellaneous reimbursement code negatively impact your willingness to prescribe Product X?
(Required.)
1: No Negative Impact
2: Minor Negative Impact
3: Moderate Negative Impact
4: Significant Negative Impact
5: Extreme Negative Impact
*
10.
Please explain your reasoning to question 9.
(Required.)
*
11.
In the scenario above with 4 new denosumab biosimilars in the market, which of the factors listed will have the greatest impact on your biosimilar choice?
(Required.)
Financial value
Clinical profile (safety and efficacy)
Patient support programs
Sales force interactions
Interchangeability to Reference Brand
Other